Literature DB >> 11032729

Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats.

C Noda1, N Tanahashi, N Shimbara, K B Hendil, K Tanaka.   

Abstract

We investigated the expression of standard proteasomes, immunoproteasomes, and their regulators, PA28, and PA700, in rat tissues. Immunoproteasomes (with subunits LMP2, LMP7, and MECL1) were abundant in the spleen but almost absent in the brain. In contrast, standard proteasomes (with X, Y, and Z) were highly expressed in the brain but not in the spleen. Both proteasome types were present in the lung and the liver. PA700 subunits (p112, S5a, and p45) were found in all tissues. PA28alpha, PA28beta, and PA28gamma were also expressed in all tissues, except for the brain which contained very little PA28beta. The results did not depend on rat sex or age. The cleavage specificity for peptide substrates differed greatly between brain and spleen proteasomes. Hybrid proteasomes, containing both PA28alphabeta and PA700, were not present in the brain but in all other tissues examined. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032729     DOI: 10.1006/bbrc.2000.3676

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  39 in total

1.  Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome.

Authors:  Can Kesmir; Vera van Noort; Rob J de Boer; Paulien Hogeweg
Journal:  Immunogenetics       Date:  2003-08-30       Impact factor: 2.846

Review 2.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 3.  Regulation of proteasome activity in health and disease.

Authors:  Marion Schmidt; Daniel Finley
Journal:  Biochim Biophys Acta       Date:  2013-08-27

4.  Immunoproteasome responds to injury in the retina and brain.

Authors:  Deborah A Ferrington; Stacy A Hussong; Heidi Roehrich; Rebecca J Kapphahn; Shannon M Kavanaugh; Neal D Heuss; Dale S Gregerson
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

5.  Comparison of rat liver and brain proteasomes for oxidative stress-induced inactivation: Influence of ageing and dietary restriction.

Authors:  Kalavathi Dasuri; Anhthao Nguyen; Le Zhang; Ok Sun Fernandez-Kim; Annadora J Bruce-Keller; Bradford A Blalock; Rafael De Cabo; Jeffrey N Keller
Journal:  Free Radic Res       Date:  2009-01

Review 6.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

7.  An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Authors:  Sondra Downey-Kopyscinski; Ellen W Daily; Marc Gautier; Ananta Bhatt; Bogdan I Florea; Constantine S Mitsiades; Paul G Richardson; Christoph Driessen; Herman S Overkleeft; Alexei F Kisselev
Journal:  Blood Adv       Date:  2018-10-09

8.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

9.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

Review 10.  The ubiquitin-proteasome system in retinal health and disease.

Authors:  Laura Campello; Julián Esteve-Rudd; Nicolás Cuenca; José Martín-Nieto
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.